Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer?

[1]  Val Gebski,et al.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. , 2007, The Lancet. Oncology.

[2]  M. Ebert,et al.  Current treatment approach to locally advanced esophageal cancer: is resection mandatory? , 2006, Future oncology.

[3]  J. Ajani,et al.  Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[5]  R. Langer,et al.  Association of Pretherapeutic Expression of Chemotherapy-Related Genes with Response to Neoadjuvant Chemotherapy in Barrett Carcinoma , 2005, Clinical Cancer Research.

[6]  A. Venturi,et al.  Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis , 2004, Gut.

[7]  J. Siewert,et al.  Improved Prognosis of Resected Esophageal Cancer , 2004, World Journal of Surgery.

[8]  F. Lordick,et al.  Neoadjuvant therapy for oesophagogastric cancer , 2004, The British journal of surgery.

[9]  Wolfgang A Weber,et al.  Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.